Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

The vast majority of acute heart failure episodes are characterized by increasing symptoms
and signs of congestion with volume overload. The goal of therapy in those patients is the …

Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors
improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in …

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Abstract Sodium–glucose cotransporter (SGLT) 2 inhibitors have been demonstrated to
reduce cardiovascular events, particularly heart failure, in cardiovascular outcome trials …

Background: Myocardial utilization of 3-hydroxybutyrate (3-OHB) is increased in patients
with heart failure and reduced ejection fraction (HFrEF). However, the cardiovascular effects …

Background: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk
of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular …

Heart failure is the most common cardiovascular reason for hospital admission for people
older than 60 years of age. Few areas in medicine have progressed as remarkably as heart …

Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibition reduces heart failure
hospitalizations in patients with diabetes, irrespective of glycaemic control. We examined the …

Importance The comparative clinical efficacy of sodium-glucose cotransporter 2 (SGLT-2)
inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) …